This trial is testing a new combination of drugs to treat advanced pancreatic cancer. The goal is to see if it is safe and works better than existing treatments.
4 Primary · 12 Secondary · Reporting Duration: First dose date to date of death, up to 1 year
211 Total Participants · 7 Treatment Groups
Primary Treatment: AB680 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: